In recent clinical trials of targeted therapies (for example, Gleevec in chronic myelogenous leukaemia, herceptin in BRCA, BRAF inhibitors in melanoma), patients who share the targeted mutation and tumour type displayed highly variable responses to the drugs66. This evidence concerns the gene BRAF and chronic myelogenous leukemia, BCR-ABL1 positive.